arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Olema Pharmaceuticals, Inc.

OLMA

$12.04 ▲ +0.23 (+1.95%) at close

8 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Olema Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.0B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -37.3% ↘

FCF / Share $-1.69 ↗

Trailing P/E —

Price / Book 2.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-162.45M

↓ -25.5% —

FCF / Share Free cash flow per share

$-1.69

↑ +5.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	15.0% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-2.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	18.3% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-45.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	47.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-106.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-25.5% Weak → Weak Stable Year-over-year change in net income	-34.0% Weak ↑ Weak Improving Year-over-year change in net income	7.8% Fair ↑ Fair Improving Year-over-year change in net income	-47.4% Weak ↑ Weak Improving Year-over-year change in net income	-221.4% Weak Weak Year-over-year change in net income	-412.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	5.2% Fair ↑ Fair Improving Year-over-year change in free cash flow	3.9% Caution ↑ Caution Improving Year-over-year change in free cash flow	10.2% Fair ↑ Fair Improving Year-over-year change in free cash flow	-55.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	53.4% Excellent Excellent Year-over-year change in free cash flow	-138.8% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—
FCF / Net Income (x)	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-37.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-34.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	32.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-33.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-6.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-33.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-326%)	-31.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-311%)	-38.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-354%)	-53.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-454%)	-25.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-267%)	-6.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	40.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+172%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-32.97x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-48.30M	$-139.48M	$-68.54M	$-23.70M	$-13.81M	$-338.55M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-1.87	$-2.20	$-2.14	$-2.62	$-1.80	$-3.42	$-1.66	—
Free Cash Flow per Share (USD)	$-1.69	$-1.78	$-1.85	$-2.06	$-1.32	$-2.84	$-1.19	—
Book Value per Share (USD)	$5.88	$5.50	$4.62	$4.90	$7.15	$8.60	$-4.09	—
Tangible Book Value per Share (USD)	$5.88	$5.50	$4.62	$4.90	$7.15	$8.60	$-4.09	—
Basic Weighted Avg Shares (shares)	87.01M	58.74M	45.25M	40.00M	39.52M	7.02M	2.59M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$463.65M	$396.71M	$244.89M	$192.35M	$281.67M	$337.55M	—	—
Total Equity (USD)	$478.56M	$408.96M	$253.90M	$197.55M	$284.57M	$338.14M	$-10.59M	$-8.40M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	$490.00K	$393.00K	$377.00K	$357.00K	$163.00K	$11.00K	$9.00K	—
Net Income, GAAP (USD)	$-162.45M	$-129.47M	$-96.66M	$-104.79M	$-71.10M	$-22.12M	$-4.32M	—
Operating Cash Flow (USD)	$-146.72M	$-104.35M	$-83.73M	$-82.06M	$-50.69M	$-19.87M	$-3.08M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters

Olema Pharmaceuticals, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare OLMA with peers